Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer

PRIMARY OBJECTIVES: I. To evaluate the efficacy of BAY 43-0006 in previously-treated, platinum-sensitive and platinum-refractory patients with measurable disease and extensive stage small cell lung cancer (E-SCLC) in terms of response rate (confirmed and unconfirmed, complete and partial). SECONDARY OBJECTIVES: I. To assess the qualitative and quantitative toxicities of BAY 43-9006 in this patient population. II. To assess overall survival in this group of patients treated with BAY 43-9006. III. To collect specimens via the Lung Cancer Specimen Repository Protocol (S9925) in order to perform exploratory analyses of the relationship between selected markers and patient outcomes. OUTLINE: This is a multicenter study. Patients are stratified according to platinum sensitivity status (platinum sensitive vs platinum refractory). Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed every 3 months for up to 2 years from study entry.